EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study



Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study



American Journal of Gastroenterology 87(4): 432-437



Arachidonic acid metabolites formed by both the cyclooxygenase and lipoxygenase pathways may contribute to the clinical diarrhea and colitis of inflammatory bowel disease. Patients with active ulcerative colitis have increased levels of leukotriene B4 in their rectal mucosa, and these levels tend to correlate with severity of the disease. In this study, we evaluated the efficacy of ingestion of fish oil n-3-omega-fatty acids, inhibitors of leukotriene synthesis, in the treatment of ulcerative colitis. Eleven patients with ulcerative colitis of mild to moderate severity were studied in a 8-month, double-blind, placebo-controlled, crossover trial of dietary supplementation with fish oil, which provided about 4.2 g of omega-3- fatty acids per day. A disease activity index based on patient symptoms and sigmoidoscopic appearance was used to assess efficacy. Mucosal leukotriene B4 production was measured by radioimmunoassay. Mean disease activity index declined 56% for patients receiving fish oil and 4% for patients on placebo (p less than 0.05). There were no statistically significant differences in histopathologic scores or colonic mucosal leukotriene B4 levels. All patients tolerated fish oil ingestion and showed no alteration in routine blood studies. No patient worsened; anti-inflammatory drugs could be reduced or eliminated in eight patients (72%) while receiving fish oil. We conclude that fish oil dietary supplementation results in clinical improvement of active mild to moderate ulcerative colitis but is not associated with significant reduction in mucosal leukotriene B4 production, compared with placebo therapy. Further studies are needed to elucidate the mechanism of action and optimal dose and duration of fish oil supplementation in ulcerative colitis.

(PDF emailed within 1 workday: $29.90)

Accession: 040150154

Download citation: RISBibTeXText

PMID: 1553930



Related references

A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 16(6): 1131-1135, 2002

Double-blind, placebo controlled trial to determine the efficacy of essential fatty acid supplementation in the treatment of ulcerative colitis. Gastroenterology 112(4 SUPPL ): A1042, 1997

Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Annals of Internal Medicine 106(4): 497-503, 1987

Oral beclometasone dipropionate in the treatment of active ulcerative colitis: A double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics 16(6): 1109-1116, June, 2002

Resveratrol Supplementation and Oxidative/Anti-Oxidative Status in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study. Archives of Medical Research 47(4): 304-309, 2016

A double blind placebo controlled multicenter study of the efficacy and safety of 5 aminosalicylic acid tablets in the treatment of ulcerative colitis. Williams, C N (Ed ) Falk Symposium, 56 Trends in Inflammatory Bowel Disease Therapy; Symposium, Halifax, Nova Scotia, Canada, June 6-9, 1990 Xviii+462p Kluwer Academic Publishers: Dordrecht, Netherlands; (Dist in The Usa And Canada By Kluwer Academic Publishers: Hingham, Massachusetts, Usa) Illus 335-340, 1991

Multicenter, randomized, double blind, placebo controlled trial of deligoparin for active ulcerative colitis. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 539, 2003

Dietary supplementation with omega-3 fatty acids in patients with active rheumatoid arthritis: a double blind placebo controlled study. Revista Medica de Chile 119(3): 267-272, 1991

Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 28(6): 758-767, 2009

Clinical trial a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics 28(6): 758-767, 2008

Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Alimentary Pharmacology & Therapeutics 19(7): 739-747, 2004

Zileuton, a 5-lipoxygenase inhibitor, in the treatment of active ulcerative colitis A double-blind, placebo controlled trial. Gastroenterology 106(4 SUPPL ): A751, 1994

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 126(5): 364-371, 1997

Repifermin for the treatment of active ulcerative colitis A randomized, double-blind, placebo-controlled, dose-escalation trial. Gastroenterology 122(4 Suppl 1): A 61, April, 2002